Abstract
There are limited data regarding the impact of asymmetric stent expansion on subsequent stent coverage and neointimal hyperplasia (NIH) in the contemporary drug-eluting stent era. EGO-BIOFREEDOM (BioFreedom stent in 105 lesions, 99 pts) and EGO-ORION (randomized Resolute vs BioMatrix stent in 119
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
